Back to search results

Green Tea and Quercetin with Docetaxel for Prostate Cancer

This study is looking at whether adding natural products, green tea and quercetin, to standard docetaxel chemotherapy can improve treatment for advanced prostate cancer (metastatic castration-resistant prostate cancer, or mCRPC). Researchers also want to understand the safety of this combination. You might be able to join if you are a man aged 18 or older with metastatic prostate cancer that has progressed. The study will compare patients receiving green tea and quercetin plus docetaxel to those receiving a placebo (an inactive substance) plus docetaxel. Success will be measured by changes in your blood prostate specific antigen (PSA) levels over 11 weeks. The current status of this study is unclear.

Study design
This interventional study plans to enroll 99 male participants. It compares two groups: one receiving green tea and quercetin with docetaxel, and another receiving a placebo with docetaxel.
What's involved
You would need to be willing to follow all study procedures and be available for the duration of the study, which includes monitoring your PSA levels from enrollment to the end of treatment at 11 weeks.
Compensation
Not stated in the trial record.
Follow-up
Efficacy will be evaluated with blood prostate specific antigen (PSA) level from enrollment to the end of treatment at 11 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06615752

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Recruiting
PHASE1Ages 18+InterventionalTreatment
Charles Drew University of Medicine and Science
~99 participants
Updated 2026-04-15 on ClinicalTrials.gov
What's tested:green tea and quercetin + docetaxelPlacebo + docetaxel

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy evaluated with blood prostate specific antigen (PSA) level
Measured over From enrollment to the end of treatment at 11 weeks

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Piwen Wang, PhD · PRINCIPAL_INVESTIGATOR · Charles Drew University of Medicine and Science

Who to contact

Piwen Wang, PhD
[email protected]
3235634999
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Signed and dated informed consent form and HIPPA (Health Insurance Portability and Accountability Act) authorization.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Male patients 18 years or older
Diagnosed with metastatic prostate cancer
History of confirmed progressive disease with concurrent use of medical castration (e.g. luteinizing hormone-releasing hormone analogue), or surgical castration
Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate
Clinical decision to start doc infusion with prednisone treatment
Adequate bone marrow function (absolute neutrophil count (ANC) more than1500 cells/mm³, platelet count more than 100,000 cells/mm³)
Adequate liver function (total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN)
Adequate renal function (serum creatinine level within normal limits)
At least a 6-month or greater life expectancy
Willing to stop consuming tea or tea-containing products and quercetin supplements throughout the entire intervention period except for the green tea extract and quercetin provided during study intervention

Exclusion

Prior treatment of chemotherapy and/or radiotherapy for metastatic disease
Any comorbid condition that would preclude the administration of docetaxel/prednisone
Ongoing alcohol abuse
Significant medical or psychiatric conditions that would make the patient a poor protocol candidate
Prior allergic reaction to tea, tea products or quercetin supplements
Allergies to multiple food items or nutritional supplements

What this trial measures

  • Efficacy evaluated with blood prostate specific antigen (PSA) levelFrom enrollment to the end of treatment at 11 weeks

    Blood PSA will be measured at baseline, 1st day of each cycle of docetaxel treatment (21 days per cycle, for 3 cycles), and at the end of the intervention.